在接受全身治疗的肝细胞癌患者治疗和生存的种族和民族差异
Kelsey S Lau-Min1,2, Angela C Tramontano3, Franklin Iheanacho4
1Division of Hematology/Oncology, Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, United States.
JNCI cancer spectrum
|October 15, 2025
概括
尽管有新的治疗方法,肝细胞癌 (HCC) 存活率的种族差异仍然存在. 与白人患者相比,亚裔和西班牙裔患者的整体存活率 (OS) 较好,新疗法使用率增加.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 健康差异 在健康上的差异
背景情况:
- 在肝细胞癌 (HCC) 治疗和生存方面存在历史性的种族和民族差异.
- 在2017年至2022年之间引入了9种全新系统性HCC疗法,这可能影响了这些差异.
研究的目的:
- 评估HCC治疗和生存的种族和民族差异的最新趋势.
- 评估新型全身疗法对不同种族和种族群体的生存结果的影响.
主要方法:
- 使用Flatiron健康研究数据库 (2011-2023) 进行回顾性队列研究.
- 包括接受全身治疗的患者,重点关注自2017年以来批准的新疗法.
- 从一线全身治疗开始确定整体存活率 (OS);多变量模型根据社会人口统计学和临床因素进行调整.
主要成果:
- 该队列包括4198名患者,53.0%是白人,11.8%是黑人,52.2%是亚洲人,11.2%是西班牙裔.
- 亚洲患者更有可能接受新疗法 (OR=1.78);与白人患者相比,黑人和西班牙裔患者的接受率相似.
- 亚洲和西班牙裔患者的中位数寿命有所改善 (10.3-10.5个月) 与白人患者 (8.0-8.3个月) 相比,也观察到更好的寿命 (亚洲HR=0.79;西班牙裔HR=0.72).
- 随着时间的推移,种族生存差异扩大,新疗法接受与改善的生存相关.
结论:
- 亚洲和西班牙裔患者在HCC中表现出优异的生存结果.
- 亚洲患者更有可能接受新的全身疗法.
- 社会和临床因素调整的最小影响表明需要进一步研究潜在的生存差异.
更多相关视频
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
553
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
553
01:21Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K